Buenos Aires’ iconic opera house, the Teatro Colón, was the stage for last night’s launch of a new botulinum toxin for the Argentina market. Clodew, a product approved by the FDA five years ago, has arrived in Argentina via the local company Oxapharma, which sealed a deal with Daewoong of South Korea. The company’s directors were present at the event along with close to 400 medical professionals.
The options for botulinum toxin treatments in the Argentine market are expanding with the entry of a fourth brand. The local company Oxapharma has launched Clodew in Argentina through a licence agreement with South Korea’s Daewoong. The product, sold as Jeuveau in the US, Nuceiva in Europe and Nabota in Asia, was approved by the FDA back in 2019. See ANMAT listing
For the Argentine launch of the product, Oxapharma threw an extravagant event at the Teatro Colón in Buenos Aires. The company founded and led by Gerardo Fossati invited close to 400 professionals from the cosmetic medicine sector and was following up today with technical conferences at the events space in Puerto Salguero led by the Brazilian doctor Jacqueline Barreto Rodrigues, who flew in for the event.
Clodew will compete in a market that’s still dominated by AbbVie’s Botox due to its age and marketing clout. The other brands on the market are Xeomin, from Germany’s Merz, and Dysport, from Ipsen, part of Switzerland-based Galderma. In the US, Daewoong’s product has gained a market share of 12% five years after its launch in 2019 thanks to a strategy of marketing to millennials, a rapid growth segment.
At yesterday’s launch, Pharmabiz joined Daewoong’s co-CEOS, Park Seong and Lee Chang-jae, along with sales director Hakkyu Lee and regional manager Elizabeth Eunae Lee. Those attending the event heard that Clodew, like similar neurotoxins, uses purified botulinum toxin to temporarily relax the small groups of muscles that cause dynamic wrinkles. Clodew is approved for glabellar lines; “crow’s feet” wrinkles; benign masseteric hypertrophy; treatment of upper extremity spasticity after stroke; and blepharospasm. It is also used for the treatment of hyperhidrosis and bruxism, among others.
